切换到内部网   |  返回旧版
首页 >> 师资建设 >> 师资队伍 >> 按职称划分 >> 副教授 >> 正文

副教授

王毅刚

发表于:2016-06-30  浏览人数:

王毅刚

别:男

出生年月:1976年12

称:副教授

细胞生物学

室: 6号楼223室

话: 0571-86843187

电子邮件:wangyigang43@163.com

主要学习工作经历

1.1995.9-1999.7 南昌大学本科学习

2.1999.8-2001.8 赣南医学院助教

3.2001.9-2004.6 南昌大学硕士研究学习

4.2002.6-2004.5 中科院上海生化与细胞所联合培养研究生

5.2006.9-2009.12 华东理工大学博士研究生学习

6.2004.7-2009.9 浙江理工大学 助理研究员

7.2009.10-2012.9 浙江理工大学 副研究员

8.2012.10-至今 浙江理工大学 副教授

主要学术及社会兼职

1. 中国细胞生物学学会会员

2. 浙江省生化与分子生物学学会会员

主要研究方向

1.肿瘤的靶向基因治疗

2.肿瘤细胞生物学

获奖与荣誉

1. 学院科研工作先进个人

2. 校本科毕业论文优秀指导教师

3. 校优秀班主任

科研教学项目

1.双靶向溶瘤腺病毒载体的构建及其在恶性肿瘤中的治疗研究(浙江理工大学科研启动基金1016845-Y2011-2013 2万

2. 基于Wnt/β-catenin信号通路探讨TSLC1在肝癌中的作用及其分子机制 (国家自然科学基金812726872013-2016 60万

3. 靶向双基因-病毒载体的策略设计及其抗恶性肿瘤的效果研究(浙江省自然科学基金LZ13H1600042013-2016 30万

专著论文

1. Zhong S, Yu D, Wang YG, Qiu S, Wu S, Liu XY*. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer. Acta Oncologica, 49(1), 91-99, 2010

2. He LF#, Wang YG#, Xiao T, Zhang KJ, Li GC, Gu JF, Chu L, Tang WH, Tan WS, Liu XY*. Suppression of cancer growth in mice by adeno-associated virus vector-mediated IFN-β expression driven by hTERT promoter. Cancer Letters, 286(2), 196-2052009 (# as first co-author)

3. Liu XP, Zhao L, Wang YG, Zhang X and Wen-Song Tan. Effects of calcium ion on adenovirus production with high densities of HEK293 cells. J Biotechnol. 15(3), 414-420, 2010

4. Wang YG, Zhang KJ, Cai HB, Wu YM, He GQ, Wen-Song Tan. The efficacy of combination therapy using Adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular Carcinoma. J Cancer Res Clin Oncol, 136(12), 1827-1837, 2010

5. Xiao LL, Li X, Niu N, Qian J, Xie G, Wang YG*. Dichloroacetate (DCA) enhances tumor cell death in combination with oncolytic adenovirus armed with MDA-7/IL-24. Mol Cell Biochem. 340(1-2), 31-40, 2010

6. Xiao LL, Wu YM, Qian J, Tan Y, Xie GL, Zhang KJ, Wang YG, Jia XY, Liu XY. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus. Cancer Biol Ther. 10(3), 242-50, 2010

7. Wang YG, He LF, He GQ, Kong YP, Liu XP, Cai HB, Liu XY and Wen-Song Tan. Enhanced antitumor effect of combining interferonβ with TRAIL mediated by tumor-targeting adeno-associated virus vector on A549 lung cancer xenograft. Chin J Biotech, 26(6), 780-788, 2010

8. Zhong S, Yu D, Wang Y, Qiu S, Wu S, Liu XY. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer. Acta Oncol, 49(1), 91-9, 2010

9. van der Laan LJ#, Wang YG#, Tilanus HW, Janssen HL, Pan Q. AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application? Expert Opin Biol Ther, 11(3), 315-27, 2011 (# as first co-author)

10. He G, Lei W, Wang S, Xiao R, Guo K, Xia Y, Zhou X, Zhang K, Liu X, WangY*. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth. J Cancer Res Clin Oncol, 138(4), 657-70, 2012

11. Zhou XM, Xie GL, Wang SB, Wang YG, Zhang KJ, Liu XY. Potent and Specific Antitumor Effect for Colorectal Cancer by CEA and Rb Double Regulated Oncolytic Adenovirus Harboring ST13 Gene. Plos one, 7(10), e47566, 2012

12. Wang SB, Tan Y, Lei W, Wang YG, Zhou XM, Zhang KJ, Chu L, Liu XY, Qian WB. Complete eradication of xenograft hepatoma by oncolytic adenovirus ZD55 harboring TRAIL-IETD-Smac gene with broad antitumor effect. Human Gene Therapy, 23(9), 992-1002, 2012